CJC-1295 and ipamorelin are the peptides most often marketed to women around menopause. They are growth hormone secretagogues, which means they prompt the body to release more of its own growth hormone. They do not contain or replace estrogen, they are not a substitute for hormone replacement therapy, and neither is FDA approved. The evidence in menopausal women is limited.
What Are the Best Peptides for Menopause?
There is no peptide proven to be the best treatment for menopause, because none has strong human trial evidence for menopause symptoms.
CJC-1295 and ipamorelin are the names that come up most. Both work on the growth hormone pathway rather than the sex hormones that change during menopause. CJC-1295 is a growth hormone-releasing hormone analog, and ipamorelin prompts growth hormone release through a different receptor. Marketing often pairs them as a "stack." The key point is that raising growth hormone is not the same as addressing the estrogen and progesterone changes that drive most menopause symptoms. Calling these the "best peptides for menopause" overstates what the research shows.
Do Peptides Replace HRT or Estrogen?
No. CJC-1295 and ipamorelin do not replace hormone replacement therapy or estrogen.
These peptides do not contain estrogen, progesterone, or testosterone, and they do not act on estrogen receptors. They influence growth hormone and IGF-1 levels. Hormone replacement therapy works by replacing the sex hormones that decline at menopause, which is a different mechanism entirely. Claims that peptides are "better than HRT" or "fully replace estrogen" are false. Women considering treatment for menopause symptoms should talk with a clinician about options with real evidence, including HRT where appropriate.
Can Peptides Reverse Menopause or Restore Fertility?
No. There is no evidence that these peptides reverse menopause or restore fertility.
From the FormBlends catalog
Sleep + Recovery Stack
Sleep and repair support with DSIP, BPC-157, and CJC · From $299/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.
View Sleep + Recovery Stack →Menopause reflects the natural decline of ovarian hormone production. Growth hormone secretagogues do not restart ovarian function, do not bring back menstrual cycles, and do not restore fertility. The live page's claim that "ipamorelin reverses menopause symptoms and restores fertility" is not supported by any clinical evidence and should be disregarded.
Are These Peptides FDA Approved?
No. Neither CJC-1295 nor ipamorelin is FDA approved.
Ipamorelin acetate was placed on the FDA's Category 2 bulk substances list in 2023, then removed from Category 2 in September 2024 after the nominator withdrew the nomination, leaving its compounding status pending Pharmacy Compounding Advisory Committee review. CJC-1295 remains restricted. Neither can currently be marketed as an approved medication. Products sold as research chemicals bypass FDA oversight and are not tested for purity, identity, or correct dosing, which is a real concern for anything injected.
What Does the Evidence Show for Sleep and Body Composition?
The honest picture is small studies and limited data, not proof for menopausal women specifically.
Growth hormone secretagogues raise growth hormone and IGF-1, which has been studied mainly for effects on body composition and sleep in small groups. Some research suggests these compounds may affect slow-wave, or deep, sleep. But evidence specific to menopausal women is limited and not conclusive. A short query about "CJC-1295 ipamorelin sleep quality" reflects real interest, yet the data does not support strong promises about better sleep or body composition in this group. More and larger studies would be needed.
How Do the Options Compare?
| Approach | What it targets | Evidence in menopause | FDA status |
|---|---|---|---|
| HRT (estrogen, progesterone) | Sex hormones that decline | Strong for many symptoms | Approved options exist |
| CJC-1295 / ipamorelin | Growth hormone pathway | Limited, small studies | Not approved |
| "Replacing estrogen" with peptides | Not a real mechanism | None | Not supported |
For menopause symptoms, treatments that act on the hormones that actually change carry the strongest evidence.
What Are the Safer, Supervised Options?
The evidence-based path for menopause runs through a clinician, not gray-market peptides.
These peptides are not approved menopause treatments. FormBlends works in the compounded GLP-1 space, with semaglutide and tirzepatide programs for medically supervised weight loss under a prescriber, which some women pursue for weight changes around midlife. That is a weight-management service, not a menopause hormone therapy, and it is mentioned here only for relevance. For menopause symptoms themselves, a clinician can discuss HRT and other evidence-based options.
Frequently Asked Questions
What are the best peptides for menopause? No peptide has strong human evidence for menopause. CJC-1295 and ipamorelin are marketed for it but act on growth hormone, not sex hormones.
Do peptides replace HRT or estrogen? No. They do not contain or replace estrogen and are not a substitute for hormone replacement therapy.
Can peptides reverse menopause or restore fertility? No. There is no evidence they reverse menopause or restore fertility.
Are CJC-1295 and ipamorelin FDA approved? No. Neither is FDA approved, and both have unsettled compounding status pending PCAC review.
Do these peptides improve sleep in menopausal women? Evidence is limited. Some small studies suggest effects on deep sleep, but data specific to menopausal women is not conclusive.
Are peptides safe for women over 50? Their safety is not established for this use, and unregulated products add risks of contamination and inaccurate dosing. No drug is risk-free.
What should I do about menopause symptoms? Talk with a clinician about evidence-based options, including HRT where appropriate.
Sources
- U.S. Food and Drug Administration, 503A bulk drug substances under evaluation and Category 2 updates. https://www.fda.gov/drugs/human-drug-compounding/list-bulk-drug-substances-under-evaluation-section-503a-fdc-act
- The Menopause Society, hormone therapy position statement and menopause care resources. https://www.menopause.org/
- National Institute on Aging, hormones and menopause information. https://www.nia.nih.gov/health/menopause
Ready when you are
Sleep + Recovery Stack
Sleep and repair support with DSIP, BPC-157, and CJC · From $299/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.
View Sleep + Recovery Stack →